RT Journal Article
SR Electronic
T1 Integrative Genomic Analysis Identifies the Soluble Receptor for Advanced Glycation End Products as Putatively Causal for Rheumatoid Arthritis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.01.20144352
DO 10.1101/2020.07.01.20144352
A1 Gha Young Lee
A1 Chen Yao
A1 Shih Jen Hwang
A1 Roby Joehanes
A1 Dong Heon Lee
A1 R. Curtis Ellison
A1 Lynn L. Moore
A1 Chunyu Liu
A1 Daniel Levy
YR 2020
UL http://medrxiv.org/content/early/2020/07/02/2020.07.01.20144352.abstract
AB Objectives Identifying causal biomarkers of rheumatoid arthritis (RA) to improve treatment and monitor disease progression remains a critical but elusive goal. To search for putatively causal protein biomarkers of RA, we designed an integrative genomic strategy utilizing Mendelian randomization (MR), which allows for causal inference between an exposure and an outcome by incorporating genetic variants associated with an exposure (circulating protein level) and inferring its effect on the outcome (rheumatoid arthritis).Methods We utilized genetic variants associated with 71 cardiovascular disease-related proteins measured in nearly 7000 Framingham Heart Study participants in conjunction with variants associated with RA in a genome-wide association study (GWAS) from the UK Medical Research Council Integrative Epidemiology Unit (19,234 cases, 61,565 controls) to identify putatively causal proteins for RA. In addition, we applied MR to study circulating rheumatoid factor (RF) levels using GWAS of RF from the UK Biobank (n=30,565) as the outcome.Results We identified the soluble receptor for advanced glycation end products (sRAGE), a critical inflammatory pathway protein, as putatively causal and protective for both RA (odds ratio per 1 standard deviation increment in inverse-rank normalized sRAGE level=0.482; 95% confidence interval 0.374-0.622; p=1.85×10−08) and RF levels (β [change in RF level per sRAGE increment]=-1.280; SE=0.434; p=0.003).Conclusions By integrating GWAS of 71 cardiovascular disease-related proteins, RA, and RF, we identified sRAGE as a putatively causal protein protective for both RA ad RF levels. These results highlight the AGER/RAGE axis as a promising new target for RA treatment.Competing Interest StatementThe National Heart, Lung, and Blood Institute and Ionis Pharmaceuticals entered into a Cooperative Research and Development Agreement (CRADA) to conduct research targeting the AGER gene, which encodes sRAGE, based in part, on the results of this research. Dr. Levy is the NHLBI principal investigator on the CRADA.Funding StatementThe Framingham Heart Study laboratory work for this project was funded by National Institutes of Health contract N01-HC-25195. The analytical component of this project was funded by the Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (D. Levy, Principal Investigator).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is an observational study that did not involve an IRB/oversight approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe pQTL and GWAS used in this study are publicly available from the supplementary files of https://www.nature.com/articles/s41467-018-05512-x and from https://gwas.mrcieu.ac.uk/datasets/, respectively. The results of this study are included in the attached supplementary file in full. https://www.nature.com/articles/s41467-018-05512-x https://gwas.mrcieu.ac.uk/datasets/